Abstract
Background Chikungunya virus (CHIKV) has expanded its geographical reach in recent decades and is an emerging global health threat. CHIKV can cause significant morbidity and lead to chronic, debilitating arthritis in up to 40% of infected individuals, impacting on livelihoods. Prevention, early identification, and clinical management are key for improving outcomes. This review aims to evaluate the availability of inclusive, evidence-based clinical management guidelines for CHIKV in a global context.
Methods Six databases were searched systematically from inception to 14th October 2021 and complemented with a grey literature search until 16th September 2021. We included CMGs providing supportive care and treatment recommendations. Two reviewers independently screened records, extracted data and assessed quality using the AGREE II tool. Findings are presented in a narrative synthesis.
Results Twenty-eight CMGs were included; most were of low-quality (median score 2 out of 7 (range 1-7)). None were produced specifically in a low-income country and 54% (15/28) were produced more than five years ago. There were variations in the CMGs’ guidance on the management of different at-risk populations, long-term sequelae, and the prevention of disease transmission in community and hospital settings. In the acute phase, 54% (15/28) recommended hospitalisation for severe cases, however only 39% (11/28) provided clinical management guidance for severe disease. Further, 46% (13/28) advocated for steroids in the chronic phase, yet 18% (5/28) advised against its use.
Conclusion There was a lack of high-quality CMGs that provided supportive care and treatment guidance; this scarcity may impact patient care and outcomes. It is essential that existing guidelines are updated and adapted to provide detailed evidence-based treatment guidelines for different at-risk populations. This study also highlights a need for more research into the management of the acute and chronic phases of CHIKV infection to inform evidence-based care.
Systematic review registration: PROSPERO CRD42020167361
What was known before
CHIKV is endemic across most of the southern hemisphere, with risk of expansion into new regions driven by global travel, trade, and climate change.
Infection can result in severe illness with long-term sequelae, particularly in vulnerable groups. Chronic sequelae of CHIKV infection is a cause of significant debilitating morbidity affecting individual functionality and quality of life with wider health system and socio-economic impact.
There is no effective vaccine or targeted treatment against Chikungunya and supportive care is the mainstay of treatment.
Even with a limited evidence base, clinical management guidelines (CMGs) are key tools for standardising best available evidence-based care, and reduce inappropriate use of treatments, to reduce morbidity and improve patient outcomes.
What this study adds
This review highlights a global scarcity of CMGs for chikungunya providing detailed guidance on optimal supportive care and treatment for different at-risk populations and settings.
There was limited guidance available on care for severe cases, and available guidance was heterogenous and discordant (e.g., on use of analgesia, corticosteroids, and monitoring).
The limited availability of up-to-date CMGs and heterogenous recommendations identified is a concern, which may impact on equity in access to best available evidence-based care and patient outcomes.
Further research into access to and implementation of CMGs in different settings is needed, to ensure equitable access to best available care.
This study also highlights a need for further investment into research into supportive care and treatment for different at-risk populations, and new evidence incorporated into guidelines to reduce morbidity and improve long term outcomes for the people affected by and at risk of Chikungunya.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=167361
Funding Statement
This work was supported by the UK Foreign, Commonwealth and Development Office, Wellcome Trust [215091/Z/18/Z], the Bill & Melinda Gates Foundation [OPP1209135]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. Peter Hart is a senior research advisor and Helen Groves is a research manager at the Wellcome Trust, which provided part of the funding for this work, but, neither had a role in data collection, analysis nor interpretation of the findings. Wellcome supports a range of research funding activities including awards made to ISARIC. URL to funders websites: Wellcome-https://wellcome.org/ The Bill & Melinda Gate's Foundation- https://www.gatesfoundation.org/
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a systematic review, no ethical approval required
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
